\-\ Texto\\:\\ \ \(0\)\
\-\ esr\\-38\\ \\(0\\-15\\)\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ nasal\\ bx\\-rare\\ granulomas\\ \ \(0\)\
\-\ serum\\ ace\\-\\ 60\\ \\(9\\-67\\)\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ w\\/\\ focal\\ caseation\ \(0\)\
\-\ afb\\ culture\\-\\ no\\ growth\\;\\ smear\\-\\ neg\\.\ \(0\)\
\-\ csf\ \(2\)\
\-\ \\-\\-\\-\ \(165\)\
\-\ hsv\\ dna\\-\\ neg\ \(0\)\
\-\ wnv\\ \\<\\ 1\\-30\ \(0\)\
\-\ fungal\\ culture\\-no\\ growth\\;\\ smear\\-\\ neg\\.\ \(1\)\
\-\ india\\ ink\\-neg\ \(1\)\
\-\ ace\\ \\<3\ \(0\)\
\-\ rbc\\-2\ \(0\)\
\-\ wbc\\-2\\ \ \(0\)\
\-\ protein\\ wnl\ \(0\)\
\-\ mass\\-like\\ meningeal\\ thickening\\ which\\ is\\ t2\\ hypointense\\ and\\ enhances\\ with\\ gadolinium\\.\\ heterogeneous\\ mass\\-like\\ sinus\\ disease\\ with\\ variable\\ enhancement\\.\\ \\ possible\\ communication\\ between\\ the\\ meningeal\\ disease\\ and\\ sinus\\ disease\\ at\\ the\\ area\\ of\\ the\\ cribriform\\ plate\\.\ \(0\)\
\-\ cns\\ sarcoidosis\ \(0\)\
\-\ neurosarcoid\ \(5\)\
\-\ fungal\\ disease\ \(5\)\
\-\ meningiomas\\ with\\ concommitant\\ sinus\\ disease\ \(1\)\
\-\ tb\\ meningitis\ \(0\)\
\-\ wegener\\ granulomatosis\ \(0\)\
\-\ 49y\\/o\\ male\\ with\\ history\\ of\\ sarcoidosis\\ presents\\ with\\ new\\ onset\\ of\\ recurrent\\ seizures\\.\ \(0\)\
\-\ the\\ patient\\'s\\ history\\ of\\ sarcoidosis\\,\\ the\\ nasal\\ biopsy\\ consistent\\ with\\ sarcoid\\,\\ and\\ imaging\\ characteristics\\ all\\ support\\ the\\ diagnosis\\ of\\ neurosarcoid\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ neg\\:\\ 0\\.3719777055841726\ \(0\)\
\-\ neurosarcoid\\:\\ 0\\.22713354398920757\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.21912239169374523\ \(0\)\
\-\ ace\\:\\ 0\\.20772918328997944\ \(0\)\
\-\ meningeal\\:\\ 0\\.1939205813863843\ \(0\)\
\-\ sinus\\:\\ 0\\.1869198952090767\ \(0\)\
\-\ disease\\:\\ 0\\.1809739529424331\ \(0\)\
\-\ nasal\\:\\ 0\\.15722157109196588\ \(0\)\
\-\ fungal\\:\\ 0\\.15436740192598686\ \(0\)\
\-\ growth\\:\\ 0\\.14220040823258215\ \(0\)\
\-\ caseation\\:\\ 0\\.1378948273734692\ \(0\)\
\-\ wnv\\:\\ 0\\.13176586922724623\ \(0\)\
\-\ cribriform\\:\\ 0\\.13176586922724623\ \(0\)\
\-\ concommitant\\:\\ 0\\.13176586922724623\ \(0\)\
\-\ india\\:\\ 0\\.1151593879258346\ \(0\)\
\-\ hsv\\:\\ 0\\.10646225790790324\ \(0\)\
\-\ afb\\:\\ 0\\.10468186477064594\ \(0\)\
\-\ the\\:\\ 0\\.10323177872619364\ \(0\)\
\-\ with\\:\\ 0\\.10130527368175943\ \(0\)\
\-\ meningiomas\\:\\ 0\\.10097662539014003\ \(0\)\
\-\ granulomas\\:\\ 0\\.09696029069319215\ \(0\)\
\-\ wegener\\:\\ 0\\.09646464397122918\ \(0\)\
\-\ granulomatosis\\:\\ 0\\.09506834080829557\ \(0\)\
\-\ communication\\:\\ 0\\.09049910223495138\ \(0\)\
\-\ of\\:\\ 0\\.08437064995822058\ \(0\)\
\-\ variable\\:\\ 0\\.08372681846026864\ \(0\)\
\-\ support\\:\\ 0\\.08372681846026864\ \(0\)\
\-\ meningitis\\:\\ 0\\.0812178085846188\ \(0\)\
\-\ wnl\\:\\ 0\\.08086626086333067\ \(0\)\
\-\ sarcoid\\:\\ 0\\.08086626086333067\ \(0\)\
\-\ cns\\:\\ 0\\.08052270355887814\ \(0\)\
\-\ protein\\:\\ 0\\.0800215790797627\ \(0\)\
\-\ plate\\:\\ 0\\.07906657497208643\ \(0\)\
\-\ characteristics\\:\\ 0\\.07906657497208643\ \(0\)\
\-\ serum\\:\\ 0\\.07732049710653974\ \(0\)\
\-\ tb\\:\\ 0\\.07678058718838944\ \(0\)\
\-\ enhances\\:\\ 0\\.07600524438281483\ \(0\)\
\-\ hypointense\\:\\ 0\\.07587980075252976\ \(0\)\
\-\ gadolinium\\:\\ 0\\.07184681861921115\ \(0\)\
\-\ seizures\\:\\ 0\\.070388737708142\ \(0\)\
\-\ recurrent\\:\\ 0\\.06913878042373157\ \(0\)\
\-\ csf\\:\\ 0\\.06813326239079429\ \(0\)\
\-\ history\\:\\ 0\\.06588697319629541\ \(0\)\
\-\ 60\\:\\ 0\\.06449323394273226\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.06240876638639414\ \(0\)\
\-\ biopsy\\:\\ 0\\.06044165040580021\ \(0\)\
\-\ new\\:\\ 0\\.059652817308659276\ \(0\)\
\-\ thickening\\:\\ 0\\.058661257268542925\ \(0\)\
\-\ possible\\:\\ 0\\.05842320714092564\ \(0\)\
\-\ no\\:\\ 0\\.056079705441570864\ \(0\)\
\-\ between\\:\\ 0\\.0560257540129151\ \(0\)\
\-\ area\\:\\ 0\\.055858726117897974\ \(0\)\
\-\ onset\\:\\ 0\\.05536843868359857\ \(0\)\
\-\ and\\:\\ 0\\.05345290605259986\ \(0\)\
\-\ focal\\:\\ 0\\.05157675095537473\ \(0\)\
\-\ all\\:\\ 0\\.05132853732073831\ \(0\)\
\-\ enhancement\\:\\ 0\\.049630430019217874\ \(0\)\
\-\ t2\\:\\ 0\\.04960844329432791\ \(0\)\
\-\ consistent\\:\\ 0\\.046753947807235297\ \(0\)\
\-\ imaging\\:\\ 0\\.04531490517793533\ \(0\)\
\-\ diagnosis\\:\\ 0\\.04469916829722685\ \(0\)\
\-\ presents\\:\\ 0\\.04147936193237237\ \(0\)\
\-\ which\\:\\ 0\\.03920801400015226\ \(0\)\
\-\ male\\:\\ 0\\.03839132201944515\ \(0\)\
\-\ at\\:\\ 0\\.032568812852058995\ \(0\)\
\-\ patient\\:\\ 0\\.02804512784584221\ \(0\)\
\-\ is\\:\\ 0\\.023613692694677262\ \(0\)\
